Barinthus prioritizes VTP-300 (CHB) and VTP-1000 (celiac); cuts workforce 25%, extends cash runway to Q2 2026

Barinthus Biotherapeutics plc.

Pipeline focused on VTP-300 for chronic hepatitis B and VTP-1000 for celiac disease; ongoing Phase 1 trial of VTP-850 in prostate cancer to be completed.
Company to undergo restructuring with workforce reduction of approximately 25% to align resources.
Cash runway expected to extend into second quarter of 2026 due to streamlined pipeline and cost cuts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.